AHCO

STRUCTURAL ANALYST NOTE: AHCO (AdaptHealth Corp.)

Date: 2026-06-13 Current Price: $9.65

1. Structural Readiness

State: Context-Only Conservative Entry: — Aggressive/Pre-Breakout Entry: — Breakout Level: — Extension: — ATR Current: 3.9% (Productive)

Analysis:

2. Thesis Layer

Thesis Classification: Tactical / Setup-Led Secular Thesis: None Named

Analysis: At this date, AHCO is classified strictly as a Tactical, setup-led name. There is no named macro or secular thesis driving the immediate conviction stack. The investment case must be judged solely on the quality of the technical setup (which is currently forming) and the underlying business fundamentals provided in the evidence. No external narrative or sector-wide tailwind is being applied to this analysis; the focus remains on the company's execution and the structural price action.

3. Business Fundamentals

Company Overview: AdaptHealth Corp. is a national leader in providing patient-centered, healthcare-at-home solutions, specifically Home Medical Equipment (HME), medical supplies, and related services. The company operates across four reportable segments: Sleep Health, Respiratory Health, Diabetes Health, and Wellness at Home. It services beneficiaries of Medicare, Medicaid, and commercial insurance payors.

Operational Scale & Growth (as of Q1 2026):

• Patient Base: As of March 31, 2026, the company serviced approximately 4.5 million patients annually across 50 states, operating through a network of approximately 670 locations in 48 states. This represents growth from 4.3 million patients and 640 locations as of December 31, 2025.
• Revenue Growth:
• Sleep Health: Net revenue grew 13.3% year-over-year to $358.5 million, driven by a record number of PAP new starts.
• Respiratory Health: Net revenue grew 7.6% year-over-year to $178.1 million, with oxygen new starts growing 12.8%.
• Total Revenue Guidance: Management raised full-year net revenue projections by $10 million to a range of $3.45 billion to $3.52 billion.
• Strategic Wins: The company established 35 de novo locations over the past couple of months and secured exclusive HME provider status for more than 10 million new members.

Financial Performance & Margins:

• EBITDA Margin: Adjusted EBITDA margin for Q1 2026 was 14.8%.
• Q2 Guidance: Management expects Q2 2026 net revenue of $840 million to $860 million and an adjusted EBITDA margin of approximately 19%.
• Cost Normalization: Management noted that Q1 included $12 million of elevated labor expense (of which $8 million was variable labor to accelerate transition), which they expect to normalize by the end of the second quarter.

Regulatory Context:

• CMS Rulemaking: On November 28, 2025, CMS issued the CY 2026 Home Health Prospective Payment System Final Rule.
• CBP Timeline: The Competitive Bidding Program (CBP) is scheduled to resume in 2026. The timeline indicates a bid window opening in late summer/early fall 2026, contract awards in late summer/early fall 2027, and full implementation no later than January 1, 2028.
• Capitation Trend: Management observes increasing interest from payors in capitated arrangements to align incentives, a trend they anticipate will persist.

4. Archetype and Conviction

Archetype: Quality Compounder Rationale: The company fits the Quality Compounder archetype due to its consistent expansion of patient reach (4.3M to 4.5M in one quarter), successful integration of new members (10 million new members), and the ability to scale revenue while managing margin expansion (guiding to 19% EBITDA margin in Q2 vs. 14.8% in Q1). The business model demonstrates resilience through diversification across Sleep, Respiratory, and Diabetes segments, and a shift toward higher-value capitated arrangements.

Valuation & Conviction Stack:

• Financial Spine: Forward consensus EPS is projected at $0.84 for FY1 and $1.17 for FY2, indicating a clear path to earnings growth.
• Conviction Drivers:
• Execution: Successful de novo expansion and acquisition of 10 million new members.
• Margin Inflection: Management expects labor costs to normalize, driving EBITDA margin expansion from 14.8% to ~19%.
• Revenue Momentum: Double-digit growth in key segments (Sleep +13.3%, Respiratory +7.6%).
• Structural Quality: The setup is currently Forming. While the fundamentals are strong, the technical structure requires a breakout to confirm the "Active" status. The current price of $9.65 is a consolidation point.
• ATR Context: The current ATR of 3.9% suggests the stock is not in a "severe loser" zone (>8%) nor a "weak" zone (<2.5%), but is in a productive volatility range suitable for building a position if the breakout occurs.

5. Invalidation, Strengthening, and Gaps

What Would Invalidate:

• A failure to normalize labor costs by the end of Q2 2026, leading to margin compression below guidance.
• Adverse regulatory outcomes from the CBP bid window opening in late summer 2026 that significantly reduce reimbursement rates.

What Would Strengthen:

• A confirmed breakout above the forming coil resistance level.
• Confirmation of the 19% EBITDA margin in the Q2 earnings report.
• Further expansion of the exclusive provider agreements beyond the 10 million member milestone.

Evidence Gaps:

• Capitation Impact: While management notes increased interest in capitated arrangements, the specific financial impact of these new contracts on the 2026 full-year bottom line is not yet quantified in the provided evidence beyond the revenue guidance.
• CBP Specifics: While the timeline is known, the specific bid amounts and contract terms resulting from the late-summer 2026 bid window are not yet available (as of June 2026).

PRIVATE ANALYST CALL

Judgment: Speculative Confidence: medium Key evidence: Management raised full-year revenue guidance to $3.52B; Q1 Sleep Health revenue grew 13.3% to $358.5M; Labor costs expected to normalize by end of Q2 2026. Key risks: Technical setup is still forming with no breakout confirmed; Regulatory uncertainty regarding CBP bid window in late summer 2026; Margin expansion depends on successful cost normalization. Sizing hint: Position size should be conservative until the coil confirms active status via breakout. Expected path: Management expects labor costs to normalize in Q2, driving EBITDA margin to ~19%; structural consolidation continues until a breakout level is established. Expected horizon: 3 to 6 months for technical confirmation and Q2 earnings validation.